Table 2 Unadjusted and adjusted associations between aspirin use and severity of acute exacerbation of chronic obstructive pulmonary disease

 In-hospital death^a

1.0% (0.8–1.1%)

1.4% (1.4–1.5%)

0.67 (0.56–0.80)

<0.001

0.60 (0.50–0.72)

<0.001

 Invasive mechanical ventilation^a

1.7% (1.5–1.9%)

2.6% (2.5–2.6%)

0.64 (0.56–0.74)

<0.001

0.64 (0.55–0.73)

<0.001

 NIPPV use^a

7.6% (7.2–8.1%)

7.2% (7.1–7.3%)

1.06 (0.99–1.13)

0.06

1.05 (0.98–1.12)

0.20

 Hospital LOS, days, median (IQR)^b

3 (2–5)

4 (2–6)

−6% (−4 to −7%)

<0.001

−7% (−5 to −9%)

<0.001

 In-hospital death^a

1.0% (0.8–1.3%)

1.3% (1.1–1.3%)

0.85 (0.67–1.09)

0.20

0.72 (0.56–0.93)

0.01

 Invasive mechanical ventilation^a

1.8% (1.5–2.1%)

2.4% (2.3–2.5%)

0.74 (0.61–0.89)

0.002

0.71 (0.59–0.87)

0.001

 NIPPV use^a

8.0% (7.3–8.7%)

7.1% (7.0–7.2%)

1.15 (1.05–1.27)

0.002

1.10 (0.99–1.21)

0.053

 Hospital LOS, days, median (IQR)^b

3 (2–5)

3 (2–5)

−2% (0 to −5%)

0.10

−5% (−2 to −8%)

<0.001

 In-hospital death^a

0.8% (0.6–1.1%)

1.0% (1.0–1.1%)

0.81 (0.59–1.11)

0.19

0.66 (0.47–0.92)

0.02

 Invasive mechanical ventilation^a

1.8% (1.5–2.2%)

2.4% (2.3–2.5%)

0.79 (0.64–0.97)

0.02

0.77 (0.62–0.95)

0.02

 NIPPV use^a

7.2% (6.5–7.9%)

6.2% (6.1–6.4%)

1.20 (1.08–1.34)

0.001

1.15 (1.03–1.29)

0.02

 Hospital LOS, days, median (IQR)^b

3 (2–5)

3 (2–5)

−1% (−4 to −2%)

0.52

−4% (−7 to −1%)

0.02